TITLE:
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

CONDITION:
HIV Infection

INTERVENTION:
efavirenz

SUMMARY:

      This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation
      containing two FDA-approved drugs in HIV-infected patients who have not received prior
      therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily
      regimen. Study physicians will evaluate subjects to determine if they have certain medical
      conditions, laboratory test values, medication use, or drug allergies that would exclude
      them from the study.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion criteria:

          -  Participants must be able to provide informed consent.

          -  Have documented HIV-1 infection.

          -  Have not received more than 14 days of prior treatment with antiretroviral drugs.

          -  Meet laboratory test criteria.

          -  Women of childbearing potential must abstain from sexual intercourse or use
             acceptable contraception.

          -  Must be able to take study medications as directed and complete all study visits and
             evaluations during the 48 week study.

        Exclusion criteria:

          -  Enrolled in other HIV treatment studies.

          -  Pregnant or breastfeeding.
      
